Prelude Therapeutics Incorporated logo
Prelude Therapeutics Incorporated PRLD
$ 1.3 46.4%

Quarterly report 2024-Q3
added 11-06-2024

report update icon

Prelude Therapeutics Incorporated Balance Sheet 2011-2024 | PRLD

Annual Balance Sheet Prelude Therapeutics Incorporated

2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Net Debt

-8.4 M - - -218 M -18.6 M -15.6 M - - - - - - -

Long Term Debt

15.4 M - - - - - - - - - - - -

Long Term Debt Current

1.48 M 1.83 M 1.74 M - - - - - - - - - -

Total Non Current Liabilities

- - - 32 K 66.4 M 36.7 M - - - - - - -

Total Current Liabilities

21.8 M 21.7 M 19.2 M 11.4 M - - - - - - - - -

Total Liabilities

40.6 M 25.1 M 19.2 M 11.4 M 71.3 M 39.1 M - - - - - - -

Deferred Revenue

- - - - - - - - - - - - -

Retained Earnings

-456 M -335 M -219 M -107 M -50.5 M -22.9 M - - - - - - -

Total Assets

278 M 220 M 305 M 224 M 21.9 M 16.4 M - - - - - - -

Cash and Cash Equivalents

25.3 M 30.6 M 31.8 M 218 M - - - - - - - - -

Book Value

237 M 195 M 286 M 212 M -49.4 M -22.7 M - - - - - - -

Total Shareholders Equity

237 M 195 M 286 M 212 M -49.4 M - - - - - - - -

All numbers in USD currency

Quarterly Balance Sheet Prelude Therapeutics Incorporated

2024-Q3 2024-Q2 2024-Q1 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Long Term Debt

15.4 M 15.5 M 15.5 M - - - - - - 390 K - 312 K 543 K 840 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Non Current Liabilities

- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Liabilities

40.8 M 42 M 36.4 M 20.3 M 18.6 M 23 M - 24.9 M 18.2 M 18.9 M 19.2 M 20 M 15.2 M 13.3 M 11.4 M 11.4 M 11.4 M 11.4 M 4.84 M 4.84 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Deferred Revenue

- 3 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Retained Earnings

-555 M -523 M -488 M -423 M -393 M -362 M - -306 M -276 M -249 M -219 M -186 M -156 M -129 M -107 M -107 M -107 M -107 M -50.5 M -50.5 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Assets

197 M 224 M 247 M 259 M 281 M 198 M - 242 M 259 M 281 M 305 M 331 M 350 M 370 M 224 M 224 M 224 M 224 M 21.9 M 21.9 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Cash and Cash Equivalents

11.1 M 27.8 M 24.7 M 15.9 M 26.4 M 18.2 M - 52 M 50.7 M 51.6 M 31.8 M 61.4 M 343 M 363 M 218 M 218 M 218 M 218 M 18.9 M 18.9 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Book Value

156 M 182 M 211 M 238 M 262 M 175 M - 217 M 241 M 262 M 286 M 311 M 334 M 357 M 212 M 212 M 212 M 212 M 17 M 17 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Shareholders Equity

156 M 182 M 211 M 238 M 262 M 175 M - 217 M 241 M 262 M 286 M 311 M 334 M 357 M 212 M 212 M 212 M 212 M -49.4 M -49.4 M -33.3 M -27.9 M -22.7 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency